Assuntos
Xantogranuloma Necrobiótico/diagnóstico , Paraproteinemias/diagnóstico , Administração Intravenosa , Adulto , Biópsia , Sedimentação Sanguínea , Medula Óssea/patologia , Ciclofosfamida/administração & dosagem , Pálpebras , Feminino , Humanos , Cadeias gama de Imunoglobulina/sangue , Imunoglobulinas Intravenosas/administração & dosagem , Xantogranuloma Necrobiótico/sangue , Xantogranuloma Necrobiótico/tratamento farmacológico , Xantogranuloma Necrobiótico/etiologia , Paraproteinemias/sangue , Paraproteinemias/complicações , Paraproteinemias/tratamento farmacológico , Pele/patologiaRESUMO
Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was associated with plasma cell dyscrasia. After treatment with cyclophosphamide, dexamethasone, and thalidomide, there was a reduction of cutaneous lesions and serum levels of monoclonal protein.
Assuntos
Xantogranuloma Necrobiótico/tratamento farmacológico , Mieloma Múltiplo Latente/tratamento farmacológico , Ciclofosfamida/uso terapêutico , Dexametasona/uso terapêutico , Feminino , Humanos , Imunossupressores/uso terapêutico , Pessoa de Meia-Idade , Xantogranuloma Necrobiótico/complicações , Xantogranuloma Necrobiótico/patologia , Mieloma Múltiplo Latente/complicações , Mieloma Múltiplo Latente/patologia , Talidomida/uso terapêutico , Resultado do TratamentoRESUMO
Abstract: Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was associated with plasma cell dyscrasia. After treatment with cyclophosphamide, dexamethasone, and thalidomide, there was a reduction of cutaneous lesions and serum levels of monoclonal protein.